Pharmacotherapy and pulmonary fibrosis risk after SARS-CoV-2 infection: a prospective nationwide cohort study in the United States - The Lancet Regional Health – Americas
Pulmonary Fibrosis Lung Disease That's Not IPF
COVID-19-associated pneumonia - wikidoc
Targeted Treatments for Chronic Obstructive Pulmonary Disease (COPD) Using Low-Molecular-Weight Drugs (LMWDs) | Journal of Medicinal Chemistry